{
    "score": [
        1.0
    ],
    "extracted": [
        8
    ],
    "abstract": [
        "mizuho trims dermira target price to $ 39.00 ."
    ],
    "id": "190647.train",
    "article": [
        "dermira had its price objective cut by mizuho from $ 43.00 to $ 39.00 in a report issued on tuesday morning , marketbeat . com reports . they currently have a buy rating on the biopharmaceutical company 's stock . `` we are maintaining our outperform rating on bellicum . at the 2017 american society of hematology meeting , the company reported immune reconstitution data from the bp-004 study of bpx-501 in pediatric patients with hematological disorders , following αβ t cell depleted haploidentical hsct . the results highlight a robust and fast adaptive immune recovery due to the expansion and persistence of bpx-501 cells . ",
        "additionally , the company presented preclinical data of its cell therapy franchise based on a controllable switch technology , showcasing an engineered myd88/cd40 cd19 car t cell with a better safety and enhanced anti-tumor activity . with bpx-501 set to drive both near-term and long-term value , the advancement of the car t/tcr franchise through clinical development , and a cash position of approximately $ 106 million , we continue to recommend shares of bellicum to long-term , risk-tolerant investors . '' , '' mizuho 's analyst wrote . derm has been the topic of several other research reports . ",
        "zacks investment research upgraded shares of dermira from a sell rating to a hold rating in a research note on thursday , august 17th . cantor fitzgerald set a $ 45.00 price target on shares of dermira and gave the stock a buy rating in a research note on wednesday , november 29th . bidaskclub upgraded shares of dermira from a sell rating to a hold rating in a research note on saturday , december 2nd . needham & company llc reiterated a buy rating and issued a $ 46.00 price target on shares of dermira in a research note on sunday , september 17th . ",
        "finally , guggenheim assumed coverage on shares of dermira in a research note on tuesday , december 5th . they issued a buy rating on the stock . four analysts have rated the stock with a sell rating , one has issued a hold rating and six have given a buy rating to the company 's stock . the stock has a consensus rating of hold and a consensus price target of $ 41.00 . shares of dermira traded down $ 0.88 during mid-day trading on tuesday , reaching $ 26.63 . 336,800 shares of the company 's stock traded hands , compared to its average volume of 427,927 . ",
        "dermira has a 1-year low of $ 21.35 and a 1-year high of $ 38.75 . the company has a debt-to-equity ratio of 1.40 , a quick ratio of 4.68 and a current ratio of 4.68 . in other news , insider eugene a. bauer sold 7,500 shares of the company 's stock in a transaction dated wednesday , october 11th . the shares were sold at an average price of $ 30.04 , for a total transaction of $ 225,300.00 . the sale was disclosed in a legal filing with the sec , which is available through this link . ",
        "also , ceo thomas g. wiggans sold 9,500 shares of the company 's stock in a transaction dated monday , september 18th . the shares were sold at an average price of $ 27.51 , for a total transaction of $ 261,345.00 . the disclosure for this sale can be found here . insiders have sold a total of 28,800 shares of company stock worth $ 809,425 over the last 90 days . corporate insiders own 13.30 % of the company 's stock . several hedge funds and other institutional investors have recently made changes to their positions in derm . ",
        "axa raised its position in dermira by 41.5 % in the 3rd quarter . axa now owns 300,333 shares of the biopharmaceutical company 's stock worth $ 8,109,000 after purchasing an additional 88,079 shares during the period . gsa capital partners llp purchased a new stake in dermira in the 3rd quarter worth about $ 696,000 . point72 asset management l. p. raised its position in dermira by 621.8 % in the 3rd quarter . point72 asset management l. p. now owns 712,904 shares of the biopharmaceutical company 's stock worth $ 19,248,000 after purchasing an additional 614,138 shares during the period . ",
        "alyeska investment group l. p. raised its position in dermira by 1.8 % in the 3rd quarter . alyeska investment group l. p. now owns 351,059 shares of the biopharmaceutical company 's stock worth $ 9,479,000 after purchasing an additional 6,270 shares during the period . finally , platinum investment management ltd. . raised its position in dermira by 60.1 % in the 3rd quarter . platinum investment management ltd. . now owns 92,400 shares of the biopharmaceutical company 's stock worth $ 2,494,000 after purchasing an additional 34,700 shares during the period . hedge funds and other institutional investors own 99.54 % of the company 's stock . ",
        "trademark violation warning : `` mizuho trims dermira target price to $ 39.00 '' was first posted by watch list news and is the sole property of of watch list news . if you are viewing this news story on another publication , it was illegally stolen and reposted in violation of u. s. & international trademark & copyright legislation . the correct version of this news story can be read at company profiledermira , inc is a biopharmaceutical company . the company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions , such as hyperhidrosis , psoriasis and acne . ",
        "its portfolio includes three late-stage product candidates : cimzia , glycopyrronium tosylate and olumacostat glasaretil .   "
    ]
}